The Practice Innovation Summit, to be held in Chicago Oct. 24–25, offers a roadmap to a smarter, stronger rheumatology practice, led by experts in operations, coding, financial sustainability and more.
Rheuminations: Why Deliberate Practice & Relentless Curiosity Matter
What does it take to become a master in rheumatology? Explore how deliberate practice, relentless curiosity & profound humility are key to true expertise.
How AI Can Make Clinical Rheumatology Research More Efficient & Fruitful
A rheumatologist with a background in biostatistics, data science & bioinformatics discusses the use of artificial intelligence in clinical research.
ACR President Warns: Access to Care Is at Risk Without Medicare Payment Reform
In a recent commentary published by Medscape, ACR President Carol Langford, MD, MHS, issues a stark warning: If Congress does not reform the physician payment system, patients may face increasing difficulty accessing essential medical services.
ACR Responds to Threats to Scientific Integrity at the CDC
On Aug. 29, the ACR issued a strong statement expressing deep concern over recent developments at the agency that could threaten the integrity of science-based public health policy.
Celebrating Interdisciplinary Collaboration: Pathways to Success
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
Rheum for Everyone, Who Am I? Episode 23 (video)
In this episode, Dr. Kumar talks about professional identity and legacy in rheumatology.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Mouth-Watering Possibilities in Sjögren’s Disease
New ACR guidelines for SARD-associated interstitial lung disease cover key recommendations for screening, monitoring and first-line treatment options.
Sjögren’s Disease: More Than Just a Syndrome
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 836
- Next Page »